Frank Leonard

New Capabilities

Active (noted in recent statement)

Pancreatic cancer has been oncology's grimmest frontier. The five-year survival rate sits at 13 percent—and for decades, patients diagnosed with locally advanced disease had essentially one option: chemotherapy that extended life by months, not years. On February 11, 2026, that changed. The Food and Drug Administration approved Optune Pax, a portable device that delivers alternating electrical fields to the abdomen, marking the first new FDA-approved treatment for locally advanced pancreatic cancer in nearly three decades.

Updated Feb 13